hVIVO plc (HVO)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 5.550 |
|---|---|
| 52-week range | 4.305 – 11.000 |
| Return, 1 month / 3 months | −15.9% / −17.2% |
| Return, 1 year / 3 years | −20.7% / −70.6% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 67.5% |
| Worst drawdown (1 year) | -44.4% |
| Average daily value traded | 8.41M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
hVIVO is a clinical research organisation based in the United Kingdom that specialises in human challenge studies, in which healthy volunteers are exposed to infectious diseases in controlled settings so that experimental medicines and vaccines can be tested. It runs these trials for pharmaceutical and biotechnology companies developing treatments for respiratory and other viral infections, and it also offers related laboratory and clinical services. Its work supports clients in the life sciences sector seeking early evidence on how well a candidate product performs.
hVIVO plc trades under the code HVO on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
hVIVO plc (HVO) trades on the London Exchange in UK. It last closed at GBX 5.550 on 23 October 2026.
Its price-based Market X-Ray is 28 out of 100 (a weak price profile), ranking 3,151 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.7% and over the last three months it fell 17.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 15 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.5% | ||
| From 52-week high | -43.4% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.2% | ||
| 6-month return | -27.0% | ||
| 12-month return, skipping the last month | -5.7% | ||
| Stability (higher is calmer) | 21 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 67.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.4% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 8.41M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.3% |
|---|---|
| 1 month | −15.9% |
| 3 months | −17.2% |
| 6 months | −27.0% |
| 1 year | −20.7% |
| 3 years | −70.6% |
| 5 years | −72.3% |
Signals
| 50-day / 200-day average | 6.279 / 7.159 |
|---|---|
| Golden / death cross (60 days) | Death, 45 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.361 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 May 2025 | GBP 0.0020 |
| 18 Apr 2024 | GBP 0.0020 |
| 4 May 2023 | GBP 0.0045 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.